Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Ajanta Pharma promoter sells ₹1,024 crore stake; mutual funds step in as buyers
A promoter entity of Ajanta Pharma has sold a 2.8% stake in the drugmaker for over ₹1,000 crore through a block deal, with Kotak Mahindra Mutual Fund and Aditya Birla Sun Life Mutual Fund emerging as the key buyers.
Promoter sells Rs 1,024 crore worth of Ajanta Pharma shares in block deal to Kotak MF and ABSL MF
A promoter entity of Ajanta Pharma sold shares worth over Rs 1,024 crore through a block deal, with Kotak Mahindra Mutual Fund and Aditya Birla Sun Life Mutual Fund acquiring the stake. The transaction comes amid strong earnings growth, healthy margins and sustained momentum in the company’s pharmaceutical business.
INR recovers momentum as local equities rebound; recent oil and dollar spike fades amid signs of easing geopolitical tensions
The Indian rupee recovered momentum to settle higher by around 28 paise at Rs 95.31 per dollar on Tuesday, supported by retreating international oil prices and small pullback in dollar overseas. Meanwhile, local equities also rebounded from two-month lows as a halt in hostilities between Israel and Iran boosted hopes that peace negotiations could move forward. Geopolitical tensions eased somewhat, the dollar weakened and Brent crude futures fell below $93 a barrel as Israel and Iran agreed to halt attacks against each other following a series of mutual attacks from Sunday night, which marked the most serious escalation since the ceasefire in April. The BSE Sensex settled 394.50 points (0.54%) higher at 73,918.76, while the NSE Nifty 50 advanced 119.10 points (0.52%) to close at 23,242.10.
Should You Own More Gold? Experts Weigh In After ETF Restrictions Across Mutual Funds
Both advisors argued that the discussion should not be limited to gold. Instead, it should prompt investors to think more broadly about diversification.
Motilal Oswal AMC’s Atul Mehra says this is the most undervalued pocket of India’s stock market - CNBC TV18
Motilal Oswal AMC’s Atul Mehra says this is the most undervalued pocket of India’s stock marketCNBC TV18
SBI in $1 billion funding for Sun Pharma’s US deal
State Bank of India is set to commit up to $1 billion to fund Sun Pharmaceutical Industries Ltd.'s $12 billion acquisition of Organon & Co. This move marks a significant step for government-run banks in financing corporate takeovers. SBI will join other global lenders in this substantial deal. The funding underscores the growing ambition of Indian companies to expand globally.
Mutual funds trim stakes in 13 midcap stocks after two quarters of buying
Mutual funds have reduced their holdings in 23 BSE midcap stocks in the March 2026 quarter, reversing earlier accumulation trends seen through mid-2025. Most of these stocks have delivered negative returns in CY26, with several falling sharply. The shift signals a cautious stance by institutional investors amid ongoing market weakness.
Motilal Oswal 'bull case' sees 71% upside in this auto parts manufacturer
Motilal Oswal said Gabriel India is undergoing a structural transformation from a single-product suspension manufacturer into a diversified mobility platform, opening up a significantly larger growth runway, and it believes it is increasingly being positioned as the primary growth vehicle of the Anand Group.
IndiGo shares gain 2% after analyst meet. Why Goldman, Morgan Stanley, others see up to 38% upside?
IndiGo shares witnessed an uptick on Tuesday after its analyst meet, where management outlined strong long-term growth plans driven by rising air travel demand and international expansion. Brokerages including Goldman Sachs, Morgan Stanley, Motilal Oswal and Elara Capital reiterated bullish views, seeing up to 38% upside despite near-term geopolitical and fuel-price risks.
690% rally in 5 years! Motilal Oswal initiates coverage on this multibagger stock, sees 30% upside - Mint
690% rally in 5 years! Motilal Oswal initiates coverage on this multibagger stock, sees 30% upsideMint
Dr. Agarwal's Shares May Rally 35% on Strong Surgical Growth, Says Motilal Oswal — Check Target Price
Motilal Oswal remains bullish on Dr. Agarwal's structural growth story, backed by its leadership in the eye-care segment and a rapidly scaling surgical franchise.
Motilal Oswal Financial jumps after HDFC Life Insurance buys stake via block deal
Motilal Oswal Financial Services rose 4.02% to Rs 853.65 after HDFC Life Insurance Company acquired a 0.30% stake in the company through a block deal on Monday, 8 June 2026.